| Literature DB >> 27705805 |
Mengling Liu1, Yingfeng Xia1, Jane Ding2, Bingwei Ye2, Erhu Zhao3, Jeong-Hyeon Choi4, Ahmet Alptekin5, Chunhong Yan5, Zheng Dong6, Shuang Huang7, Liqun Yang3, Hongjuan Cui3, Yunhong Zha8, Han-Fei Ding9.
Abstract
High-risk neuroblastoma remains one of the deadliest childhood cancers. Identification of metabolic pathways that drive or maintain high-risk neuroblastoma may open new avenues of therapeutic interventions. Here, we report the isolation and propagation of neuroblastoma sphere-forming cells with self-renewal and differentiation potential from tumors of the TH-MYCN mouse, an animal model of high-risk neuroblastoma with MYCN amplification. Transcriptional profiling reveals that mouse neuroblastoma sphere-forming cells acquire a metabolic program characterized by transcriptional activation of the cholesterol and serine-glycine synthesis pathways, primarily as a result of increased expression of sterol regulatory element binding factors and Atf4, respectively. This metabolic reprogramming is recapitulated in high-risk human neuroblastomas and is prognostic for poor clinical outcome. Genetic and pharmacological inhibition of the metabolic program markedly decreases the growth and tumorigenicity of both mouse neuroblastoma sphere-forming cells and human neuroblastoma cell lines. These findings suggest a therapeutic strategy for targeting the metabolic program of high-risk neuroblastoma.Entities:
Keywords: MYCN; TH-MYCN mouse; cancer metabolism; cholesterol biosynthesis; high-risk neuroblastoma; mevalonate pathway; neuroblastoma stem cells; serine-glycine biosynthesis; statin
Mesh:
Substances:
Year: 2016 PMID: 27705805 PMCID: PMC5536348 DOI: 10.1016/j.celrep.2016.09.021
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423